1. Petkovich M et al: A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330:444, 1987
2. Giguere V et al: Identification of a receptor for the morphogen retinoic acid. Nature 330:624, 1987
3. Yu VC et al: RXRβ: A co-regulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response element. Cell 67:1251, 1991
4. Levin AA et al: 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRa. Nature 355: 359, 1992
5. Bernard BA:
Adapalene, a new chemical entity with retinoid activity.
Skin Pharmacol 6:61, 1993
6. Nagpal S, Athanikar J, Chandraratna RA: Separation of transactivation and AP1 antagonism functions of retinoic acid receptor α. J Biol Chem 270:923, 1995
7. Querfeld C et al:
Bexarotene in the treatment of cutaneous T-cell lymphoma.
Expert Opin Pharmacother 7:907, 2006
8. Elder JT et al: Differential regulation of retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 98:673, 1992
9. Fisher GJ et al: Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem 269:20629, 1994
10. Xiao JH et al: Endogenous retinoic acid receptor-retinoid X receptor heterodimers are the major functional forms regulating retinoid-responsive elements in adult human keratinocytes. J Biol Chem 270:3001, 1995
11. Wang Z et al: Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic-acid pretreatment. Nat Med 5:418, 1999
12. Kang S et al: Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol 105:549, 1995
13. Aström A et al: Retinoic acid induction of human cellular retinoic acid-binding protein-II gene transcription is mediated by retinoic acid receptor-retinoid X receptor heterodimers bound to one far upstream retinoic acid-responsive element with 5-base pair spacing. J Biol Chem 269:22334, 1994
14. Fisher GJ et al: All-trans retinoic acid induces cellular retinol-binding protein in vivo. J Invest Dermatol 105:80, 1995
15. Rosenthal DS et al: Acute or chronic topical retinoic acid treatment of human skin in vivo alters the expression of epidermal transglutaminase, loricrin, involucrin, filaggrin, and keratins 6 and 13 but not keratins 1, 10, and 14. J Invest Dermatol 98:343, 1992
16. Kang S et al: Liarozole inhibits human epidermal retinoic acid 4-hydroxylase activity and differentially augments human skin responses to retinoic acid and retinol in vivo. J Invest Dermatol 107:183, 1996
17. Feng X et al: Suprabasal expression of a dominant-negative RXRα mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids. Genes Dev 11:59, 1997
18. Xiao JH et al: Identification of heparin-binding EGF-like growth factor as a target in intercellular regulation of epidermal basil cell growth by suprabasal retinoic acid receptors. EMBO J 18:1539, 1999
19. Varani J et al: Heparin-binding, epidermal-growth-factor-like growth factor activation of keratinocyte ErbB receptors mediates epidermal hyperplasia, a prominent side-effect of retinoid therapy. J Invest Dermatol 117:1335, 2002
20. Rittié L et al: Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands
heparin binding-EGF and amphiregulin in human skin in vivo.
J Invest Dermatol 126:732, 2006
21. Heyman RA et al: 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68:397, 1992
22. Kurlandsky SB et al: Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes. J Biol Chem 271:15346, 1996
23. Duell EA, Kang S, Voorhees JJ: Retinoic acid isomers applied to human skin in vivo each induce a 4-hydroxylase that inactivates only trans retinoic acid. J Invest Dermatol 106:316, 1996
24. Reynolds NJ et al: Retinoic acid metabolites exhibit biological activity in human keratinocytes, mouse melanoma cells and hairless mouse skin in vivo. J Pharmacol Exp Ther 266:1636, 1993
25. Duell EA et al: Human skin levels of retinoic acid and cytochrome P-450-derived 4-hydroxyretinoic acid after topical application of retinoic acid in vivo compared to concentrations required to stimulate retinoic acid receptor-mediated transcription in vitro. J Clin Invest 90:1269, 1992
26. Pavez Lorie E et al: Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br J Dermatol 160:26, 2009
27. Kang S et al:
Tazarotene cream for the treatment of facial photodamage: A multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1%
tazarotene creams with
tretinoin emollient cream applied once daily for 24 weeks.
Arch Dermatol 137:1597, 2001
28. Cho S et al: Long term treatment of photoaged human skin with topical retinoic acid improves epidermal cell atypia and thickens
collagen band in the papillary dermis.
J Am Acad Dermatol 53:769, 2005
29. Griffiths CE et al: Two concentrations of topical
tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation: A double-blind, vehicle controlled comparison of 0.1% and 0.025%
tretinoin creams.
Arch Dermatol 131:1037, 1995
30. Griffiths CE et al: Restoration of
collagen formation in photodamaged human skin by
tretinoin (retinoic acid).
N Engl J Med 329:530, 1993
31. Kang S et al: Assessment of
adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial.
J Am Acad Dermatol 49:83, 2003
32. Wu K et al: Supression of mammary tumorigenesis in transgenic mice by RXR-selective retinoid, LGD 1069. Cancer Epidemiol Biomarkers Prev 11:467, 2002
33. Rizvi NA et al: Phase I study of LGD 1069 in adults with advanced cancer. Clin Cancer Res 5:1658, 1999
34. Guo W, Gill PS, Antakly T: Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 55:823, 1995
35. Nagpal S et al: Retinoid antagonism of NF-IL6: Insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma. Mol Cell Biol 17:4159, 1997
36. Sidell N et al: Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 146:3809, 1991
37. Issacs CE et al: Inhibition of herpes simplex virus replication by retinoic acid. Antiviral Res 33:117, 1997
38. Xu J, Drew PD: 9-cis-retinoic-acid suppress inflammatory responses of microglia and astrocytes. J. Neuroimmunol 171:135, 2006
39. Cheer SM, Foster RH: Alitertinoin. Am J Clin Dermatol 1:307, 2000
40. Bulengo-Ransby SM et al: Topical
tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients.
N Engl J Med 328:1438, 1993
41. Griffiths CE et al: Topical
tretinoin (retinoic acid) treatment of hyperpigmented lesions associated with photoaging in Chinese and Japanese patients: A vehicle-controlled trial.
J Am Acad Dermatol 30:76, 1994
42. Kimbrough-Green CK et al: Topical retinoic acid (
tretinoin) for melasma in black patients: A vehicle-controlled clinical trial.
Arch Dermatol 130:727, 1994
43. Kang S et al: Topical
tretinoin (retinoic acid) improves early stretch marks.
Arch Dermatol 132:519, 1996
44. Griffiths CE et al: Topical
tretinoin (retinoic acid) improves melasma: A vehicle-controlled clinical trial.
Br J Dermatol 129:415, 1993
45. Esgleyes-Ribot T et al: Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 30:581, 1994
46. Saurat JH et al: Topical retinaldehyde on human skin: Biologic effects and tolerance. J Invest Dermatol 103:770, 1994
47. Varani J et al: Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates
collagen accumulation in naturally aged human skin.
J Invest Dermatol 114:480, 2000
48. Kafi R et al: Improvement of naturally aged skin with vitamin A (retinol). Arch Dermatol 143:606, 2007
49. Breneman D et al: Phase 1 and 2 trial of
bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Arch Dermatol 138:325, 2002
50. Heald P, Mehlmauer M, Martin AG: Worlwide
Bexarotene Study Group. Topical
bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphomas: Results of the Phase III clinical trial.
J Am Acad Dermatol 49:801, 2003
51. Buchan P et al: Repeated topical administration of all-trans-retinoic acid and plasma levels of retinoic acids in humans. J Am Acad Dermatol 30:428, 1994
52. Jick SS, Terris BZ, Jick H: First trimester topical
tretinoin and congenital disorders.
Lancet 341:1181, 1993
53. Fisher GJ et al: Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379:335, 1996
54. Soballe PW et al: Carcinogenesis in human skin grafted to SCID mice. Cancer Res 56:757, 1996
55. Fisher GJ et al: Retinoic acid inhibits induction of c-JUN protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 101:1432, 1998
56. Saez E et al: C-Fos is required for malignant progression of skin tumors. Cell 82:721, 1995
57. Meunier L et al: Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, α2 integrin critically involved in T-cell activation. J Invest Dermatol 103:775, 1994
58. Kang S et al: The retinoid X receptor agonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor
ketoconazole increase activity of 1,25-dihydroxyvitamin D
3 in human skin in vivo.
J Invest Dermatol 108:513, 1997